Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Fuji
McKinsey
Covington
Express Scripts
Mallinckrodt
Deloitte
US Department of Justice

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LENALIDOMIDE

« Back to Dashboard

Clinical Trials for Lenalidomide

Trial ID Title Status Sponsor Phase Summary
NCT00031941 CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy Completed National Cancer Institute (NCI) Phase 1 RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00031941 CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy Completed National Institutes of Health Clinical Center (CC) Phase 1 RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
NCT00036894 CC-5013 in Treating Patients With Recurrent Glioma Completed National Cancer Institute (NCI) Phase 1 RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
NCT00046735 Phase 1 Study OF CDC-501 in Patients With Solid Tumors Completed Celgene Corporation Phase 1 To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.
NCT00056160 CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Corporation Phase 3 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lenalidomide

Condition Name

Condition Name for Lenalidomide
Intervention Trials
Multiple Myeloma 255
Chronic Lymphocytic Leukemia 44
Lymphoma 34
Myeloma 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lenalidomide
Intervention Trials
Multiple Myeloma 377
Neoplasms, Plasma Cell 368
Lymphoma 169
Leukemia 118
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lenalidomide

Trials by Country

Trials by Country for Lenalidomide
Location Trials
Canada 208
Japan 99
United Kingdom 88
Australia 78
Belgium 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lenalidomide
Location Trials
New York 173
Texas 149
California 147
Ohio 126
Florida 121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lenalidomide

Clinical Trial Phase

Clinical Trial Phase for Lenalidomide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 87
Phase 2/Phase 3 7
[disabled in preview] 522
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lenalidomide
Clinical Trial Phase Trials
Recruiting 218
Completed 195
Active, not recruiting 186
[disabled in preview] 138
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lenalidomide

Sponsor Name

Sponsor Name for Lenalidomide
Sponsor Trials
Celgene Corporation 264
National Cancer Institute (NCI) 138
Celgene 65
[disabled in preview] 92
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lenalidomide
Sponsor Trials
Other 781
Industry 621
NIH 148
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health
Accenture
Deloitte
US Army
Mallinckrodt
AstraZeneca
QuintilesIMS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.